Nilotinib (AMN-107)

Catalog No.S1033

Nilotinib (AMN-107) Chemical Structure

Molecular Weight(MW): 529.52

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 210 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 50 Publications

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Description Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.
Features A selective inhibitor of native and mutant Bcr-Abl.
Targets
Bcr-Abl [1]
(Murine myeloid progenitor cells)
<30 nM
In vitro

Nilotinib inhibits proliferation, migration, and actin filament formation, as well as the expression of α-SMA and collagen in activated HSCs. Nilotinib induces apoptosis of HSCs, which is correlated with reduced bcl-2 expression, increases p53 expression, cleavage of PARP, as well as increases expression of PPARγ and TRAIL-R. Nilotinib also induces cell cycle arrest, accompanied by increased expression of p27 and downregulation of cyclin D1. Interestingly, Nilotinib not only inhibits activation of PDGFR, but also TGFRII through Src. Nilotinib significantly inhibits PDGF and TGFβ-simulated phosphorylation of ERK and Akt. Furthermore, PDGF- and TGFβ-activated phosphorylated form(s) of Abl in human HSCs are inhibited by Nilotinib. [2] Nilotinib inhibits most imatinib-resistant Bcr-Abl mutations, except for T315I. [3] Nilotinib inhibits PDGF-DD-mediated ERK1/2 activation, basal and PDGF-DD-mediated activation of PDGFRβ and Akt, and schwannoma proliferation. Nilotinib is more potent than imatinib, exerting its maximal inhibitory effect at concentrations lower than steady-state trough plasma levels. [4] Nilotinib also significantly reduces the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Nilotinib treatment also significantly inhibits the PDGF-induced proliferation of lung fibroblasts. [5] Nilotinib inhibits the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values ≤12 nM. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell Ml74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmOxTWM2OD1yLkCwNFE1PCEQvF2= Mn:1V2FPT0WU
KU812 MnzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nMTmlEPTB;MD6wNFI1QCEQvF2= NVHHdYxwW0GQR1XS
EM-2 NEPIfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMEC0NUDPxE1? MVPTRW5ITVJ?
LAMA-84 MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn1PWJKSzVyPUCuNFA1QSEQvF2= NVfmfWNoW0GQR1XS
MEG-01 MojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMEC4Nlgh|ryP NHrEVHdUSU6JRWK=
BV-173 M2\mSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqxWXZKSzVyPUCuNFExQDlizszN M4\DenNCVkeHUh?=
KASUMI-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16yXGlEPTB;MD6wNlQyOyEQvF2= M{nWNnNCVkeHUh?=
NB7 M17xZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrzTWM2OD1yLkGzOFM6KM7:TR?= MkfoV2FPT0WU
BHT-101 NUDpfI9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HrN2lEPTB;MD62OFI3OyEQvF2= M2r2SHNCVkeHUh?=
CGTH-W-1 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrrZ3hyUUN3ME2wMlY1QDdizszN M2LRSHNCVkeHUh?=
HMV-II NFHufYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXOTWM2OD1yLke0PFc1KM7:TR?= MorsV2FPT0WU
NKM-1 NX;xXoV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIToTlZKSzVyPUCuPVAyPSEQvF2= MU\TRW5ITVJ?
LB2241-RCC NHnXZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrQTWM2OD1zLkCyNlI5KM7:TR?= NHrBT|RUSU6JRWK=
NCI-H1703 NVfs[VE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLiXoNKSzVyPUGuNVg5PyEQvF2= NGiwSIlUSU6JRWK=
BE-13 NHq0eJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\zTWM2OD1zLkK3OFE3KM7:TR?= M{TveHNCVkeHUh?=
ACN NV74RWRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO5RmFKSzVyPUGuOVUxPzdizszN MUTTRW5ITVJ?
A204 NFrnVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXqOlhKSzVyPUGuOVczODVizszN M4r4NHNCVkeHUh?=
HOP-62 NFXUOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj1TWM2OD1zLkiyNFc4KM7:TR?= M4HDXXNCVkeHUh?=
H9 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvEflZ{UUN3ME2yMlc{Pzl|IN88US=> NYPSU4N2W0GQR1XS
HCC1806 NFP0dm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjNbFZKSzVyPUKuO|Q{OjdizszN MorSV2FPT0WU
NOS-1 NWrDSoNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\xTHlKSzVyPUKuPFcyODJizszN NEDBcmJUSU6JRWK=
RS4-11 MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHHToFoUUN3ME2yMlkxPjJ|IN88US=> MmHnV2FPT0WU
JAR Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPTdXpxUUN3ME2yMlkzODh2IN88US=> MlziV2FPT0WU
T98G NWO3d41LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfhUmRKSzVyPUOuNFE{OTNizszN NHHufIlUSU6JRWK=
NCI-SNU-1 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\GWGlEPTB;Mz60NFA6OiEQvF2= M{XOb3NCVkeHUh?=
SK-MEL-1 NGP0c5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzE[mVKSzVyPUOuOFMxOjlizszN MWjTRW5ITVJ?
L-363 MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDRTWM2OD1|Lk[xNVA4KM7:TR?= MoLiV2FPT0WU
SW982 Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW0TXI5UUN3ME2zMlY1OTZ7IN88US=> M{nZO3NCVkeHUh?=
HT-1080 M3;hXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonwTWM2OD1|LkmxO|c2KM7:TR?= NF;LTpVUSU6JRWK=
G-402 M2rrPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPETWM2OD12LkOxNlA{KM7:TR?= M17HS3NCVkeHUh?=
HOS MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTRwOECyPFIh|ryP MUXTRW5ITVJ?
SK-NEP-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTRwOEOxPVEh|ryP NFzuNWRUSU6JRWK=
HAL-01 NEDi[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPEN2hKSzVyPUSuPFgzPDJizszN MWDTRW5ITVJ?
SBC-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH0TWM2OD12LkmwPVA4KM7:TR?= NFPHd2hUSU6JRWK=
CTV-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS4dmlKSzVyPUWuOFg6OzhizszN MljzV2FPT0WU
LCLC-103H MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe3NWltUUN3ME21Mlc4PDdzIN88US=> Mn;WV2FPT0WU
RVH-421 M3PwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLBTWM2OD13Lke3OVM3KM7:TR?= M2DUVXNCVkeHUh?=
K-562 NHjufGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTVwOUCzOkDPxE1? NIHNNZZUSU6JRWK=
CAL-33 MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\KOopKSzVyPU[uN|E{PTlizszN MlHsV2FPT0WU
MDA-MB-361 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G1TmlEPTB;Nj6zN|Y6QSEQvF2= MXjTRW5ITVJ?
IGROV-1 NXn5fGZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXyyUVJ2UUN3ME22MlQ4OTlzIN88US=> NXjDcoEzW0GQR1XS
NY NFWySWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO1TWM2OD14LkWzOVk6KM7:TR?= NX:yU5RyW0GQR1XS
Ramos-2G6-4C10 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPDS4NKSzVyPU[uOlY6OzFizszN M4rvVHNCVkeHUh?=
HuO9 M1P1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofvTWM2OD14LkezPVY1KM7:TR?= M4\pTnNCVkeHUh?=
MS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3Pcm1KSzVyPUeuNVE6PTNizszN M2G5N3NCVkeHUh?=
RPMI-8226 NXTUeJNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTdwMkiyPFch|ryP Ml3ZV2FPT0WU
HDLM-2 MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnNPJJzUUN3ME23MlQxOTR7IN88US=> MYrTRW5ITVJ?
D-566MG NFO1fJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO5TWM2OD15LkS3NVU2KM7:TR?= NVrxUXJkW0GQR1XS
SK-MEL-24 NXzuO5ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTdwNkOzPVIh|ryP NFXsOWxUSU6JRWK=
COLO-679 Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrHfmdpUUN3ME23Mlk5PjdzIN88US=> MmjiV2FPT0WU
EW-13 MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{GxXGlEPTB;OD6zNlA2PCEQvF2= NYXRSlByW0GQR1XS
A388 NWH6TnFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP6TWM2OD16LkO4OFgyKM7:TR?= MY\TRW5ITVJ?
UM-UC-3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK1eW1KSzVyPUiuOFM6PTZizszN M13LSnNCVkeHUh?=
NUGC-3 M3XJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRThwNUO1PFIh|ryP MXXTRW5ITVJ?
COLO-668 M{D5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRThwNUm0PVEh|ryP NV:x[JFEW0GQR1XS
MOLT-4 NWS3OJlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DuUmlEPTB;OD62NlM2OyEQvF2= M17IXXNCVkeHUh?=
D-423MG M3;uXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjmN4pPUUN3ME24Mlg{PzV4IN88US=> NFPZVFhUSU6JRWK=
CTB-1 NULGS2V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzLcWVKSzVyPUiuPFcyOjhizszN M2mzRnNCVkeHUh?=
BCPAP M1vaUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHqdIF3UUN3ME25MlAzPTZ{IN88US=> NYLuXZFjW0GQR1XS
GCT NFPKNHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTlwMEm4N|Eh|ryP MnP6V2FPT0WU
ACHN NXfkdIhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXFXpNKSzVyPUmuNlM3OzJizszN NUDmWVliW0GQR1XS
KYSE-520 Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml2yTWM2OD17LkOzOFgzKM7:TR?= MnXrV2FPT0WU
LB771-HNC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Hwb2lEPTB;OT63OlQ6PyEQvF2= MVXTRW5ITVJ?
MLMA NHXHfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrzTWM2OD1zMD6wNVMzKM7:TR?= MmG1V2FPT0WU
HEC-1 NGnoeW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrxe2t4UUN3ME2xNE4zQDB2IN88US=> MkLiV2FPT0WU
HL-60 NIXGUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm1WVRKSzVyPUGwMlY5PTNizszN NUL5e5k5W0GQR1XS
A101D NGO2VoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTFyLki5NlMh|ryP NWfWSoh7W0GQR1XS
A2058 NVvNNVdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HCfGlEPTB;MUCuPVI1PSEQvF2= MVPTRW5ITVJ?
KARPAS-45 NXroTGppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX2wcFlWUUN3ME2xNU4xPjN3IN88US=> M4S2cXNCVkeHUh?=
697 NVz3U|dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED2cXNKSzVyPUGxMlIyODFizszN MonUV2FPT0WU
NCI-N87 MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XQNmlEPTB;MUGuO|c{OSEQvF2= MnjzV2FPT0WU
DSH1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\STphDUUN3ME2xNU44QTV|IN88US=> NVPSRmxDW0GQR1XS
HLE NEDEXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTFzLki4N|kh|ryP NIrTWXZUSU6JRWK=
NCI-H720 MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP2b2lsUUN3ME2xNk43QDBzIN88US=> M13yZnNCVkeHUh?=
EW-3 M4jnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n6dWlEPTB;MUKuPVMxPyEQvF2= NVvjfIpXW0GQR1XS
AGS M4fm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TXN2lEPTB;MUOuNFM2OSEQvF2= M2niPHNCVkeHUh?=
ES5 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHzZXl{UUN3ME2xN{4xPTF{IN88US=> MXHTRW5ITVJ?
DB NHrpfpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrNNYxKSzVyPUGzMlMzPTZizszN Mke5V2FPT0WU
A4-Fuk M4DwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q3V2lEPTB;MUOuOFExOiEQvF2= MYHTRW5ITVJ?
A427 NH[zeFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\wc2lEPTB;MUOuOFk4OiEQvF2= M1foVnNCVkeHUh?=
MN-60 NYDZblM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XwUmlEPTB;MUOuOVg1OyEQvF2= M{KycnNCVkeHUh?=
HCC2218 NYHwOoxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF|LkW4OVYh|ryP MmjLV2FPT0WU
MV-4-11 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj2TWM2OD1zMz64NVM4KM7:TR?= Mmq1V2FPT0WU
GI-1 NYXFe3JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLoTWM2OD1zND6xNVg1KM7:TR?= NIjZflBUSU6JRWK=
JVM-3 M3LwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF2LkK2OVYh|ryP NWLVXppIW0GQR1XS
NCI-H2029 NUTidXQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPHWopKSzVyPUG0MlI4OjdizszN NWO1Zml5W0GQR1XS
TE-12 M3PkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTF2Lk[wOFYh|ryP MXnTRW5ITVJ?
WM-115 NX25VVNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzpem1VUUN3ME2xOU42Pjh|IN88US=> NXfzRlNxW0GQR1XS
BB65-RCC M4rzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX0XJpKSzVyPUG2MlAzPDFizszN NU\jVXFEW0GQR1XS
NCI-H1693 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF4LkO4NFIh|ryP NH\kUZhUSU6JRWK=
KARPAS-299 MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP2TWM2OD1zNj62NlA{KM7:TR?= NETIboxUSU6JRWK=
UACC-257 NF3jXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D4VWlEPTB;MUeuNFU5OiEQvF2= NWW2RmFNW0GQR1XS
RKO MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\oWGVKSzVyPUG3MlY1OzNizszN MoHCV2FPT0WU
HT-29 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:wTWM2OD1zNz63PFg6KM7:TR?= NWe5OIlPW0GQR1XS
ES7 NFXWbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LvS2lEPTB;MUiuNVEzOiEQvF2= NWPRdWtNW0GQR1XS
DEL MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn33TWM2OD1zOD6zNVczKM7:TR?= NIHqflNUSU6JRWK=
BT-549 NYm1blVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXCWlNTUUN3ME2xPE41ODl{IN88US=> M{f5dnNCVkeHUh?=
NCI-H1755 M3TkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvQZnZKSzVyPUG4MlU4OjNizszN NHr1W4dUSU6JRWK=
HCE-T M4P4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[0bJNKSzVyPUG4Mlg{PDFizszN MkDhV2FPT0WU
LU-139 NYTw[|hmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTF7LkC0OVgh|ryP M2L3XXNCVkeHUh?=
ECC10 M1Lh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPhO5dZUUN3ME2xPU4zPDd3IN88US=> MkXNV2FPT0WU
769-P M3roXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTBUXpKSzVyPUG5MlY{OzVizszN MXLTRW5ITVJ?
BALL-1 M2[yW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37BWmlEPTB;MUmuOlc4PSEQvF2= MUfTRW5ITVJ?
LXF-289 NI[0XZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\pTWM2OD1zOT64PVc6KM7:TR?= NXjnXW5RW0GQR1XS
TYK-nu MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX0S2xKSzVyPUG5Mlk{OTVizszN NHq1T5pUSU6JRWK=
NCI-H630 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3lTWM2OD1zOT65N|c5KM7:TR?= MnfXV2FPT0WU
EW-18 M2DOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJyLkO4NFIh|ryP Mn;1V2FPT0WU
KYSE-150 NIm4SmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJyLkewOFch|ryP MkHxV2FPT0WU
LOXIMVI NHuxeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\yZnMzUUN3ME2yNE44PTh4IN88US=> M3z6fXNCVkeHUh?=
HuP-T3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fJTmlEPTB;MkGuNFg2OiEQvF2= NX74OoxXW0GQR1XS
MFE-280 NGjVVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DYfmlEPTB;MkGuOVY4QSEQvF2= MWfTRW5ITVJ?
SK-OV-3 NEHQd2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILl[XlKSzVyPUKxMlg1ODhizszN M1XGVXNCVkeHUh?=
QIMR-WIL NVLpPFRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGKwepdKSzVyPUKyMlA1PzhizszN NHu4e5JUSU6JRWK=
NCI-H69 NGLpeW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4GxdGlEPTB;MkKuOFI6QSEQvF2= NXTxWGpQW0GQR1XS
TE-5 NHKzT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2wWpJNUUN3ME2yNk41QTZ3IN88US=> M4XNUnNCVkeHUh?=
NCI-H1993 NHHT[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f1fmlEPTB;MkKuOFk4OSEQvF2= MYjTRW5ITVJ?
NCI-H1092 NIHH[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHiVVlwUUN3ME2yN{4zQDR|IN88US=> MmHOV2FPT0WU
RH-1 M2DLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHhTWJbUUN3ME2yN{42OzV5IN88US=> MmjJV2FPT0WU
DBTRG-05MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJ|Lki0O|Ih|ryP NH;I[4pUSU6JRWK=
Mo-T NFvpNYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L4SGlEPTB;MkOuPUDPxE1? NGHUcnpUSU6JRWK=
HD-MY-Z MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjqPHoyUUN3ME2yOE4zOzZ{IN88US=> M{LsOnNCVkeHUh?=
NCI-H2342 M3LDSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq2TWM2OD1{ND62O|Y4KM7:TR?= NWTxU2tPW0GQR1XS
C32 M3zDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XkPWlEPTB;MkSuPVU4PiEQvF2= M3rKSXNCVkeHUh?=
HTC-C3 NFfoWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrPUFBKSzVyPUK1MlM2PzdizszN NYHK[ZJIW0GQR1XS
NCI-H358 NUXRVI81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmftTWM2OD1{NT6zPVQ{KM7:TR?= NYX6UXhOW0GQR1XS
CAL-85-1 NEPUTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJ3LkS1O|ch|ryP MV;TRW5ITVJ?
HT-1197 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJ3LkWzNVkh|ryP NYnVW2hqW0GQR1XS
A172 M2PBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJ3LkexN|Yh|ryP M2PVd3NCVkeHUh?=
SW1573 NEjQeGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJ3Lke3PFUh|ryP MXzTRW5ITVJ?
EW-24 NWLnepp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;FTmNKSzVyPUK1Mlk3OiEQvF2= NEOyeXlUSU6JRWK=
SK-MEL-2 MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rmOWlEPTB;Mk[uNFMyOiEQvF2= MnvCV2FPT0WU
LU-65 NXrCW5JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr1blNoUUN3ME2yOk4xPDV{IN88US=> NWOyOol2W0GQR1XS
KMOE-2 M1HTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn6zTWM2OD1{Nj6wPVE2KM7:TR?= M{DsWXNCVkeHUh?=
H-EMC-SS MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LTW2lEPTB;Mk[uOFEyPCEQvF2= NUDGNmo1W0GQR1XS
H4 NU\we5FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X3Z2lEPTB;Mk[uOFI1OyEQvF2= MX;TRW5ITVJ?
DU-4475 M2XRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJ5LkG4O|Ih|ryP NFrGWpBUSU6JRWK=
HCT-116 M1HCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C1SmlEPTB;MkeuOFM1QSEQvF2= NIrFfpVUSU6JRWK=
MSTO-211H M{DnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnnPY5KSzVyPUK3MlYzPTVizszN M3fHUnNCVkeHUh?=
NCI-H292 NEfiR|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\xUGJKSzVyPUK3Mlk3OTdizszN MkTIV2FPT0WU
NCI-H446 M324Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTJ6LkKxNFUh|ryP NIHIXJdUSU6JRWK=
NCI-H2009 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjab3NyUUN3ME2yPU4yPDNzIN88US=> NETyNGNUSU6JRWK=
MHH-ES-1 NIPTW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJ7LkO2PFUh|ryP NFf3fWtUSU6JRWK=
TI-73 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f5PWlEPTB;MkmuOFAxOSEQvF2= MVrTRW5ITVJ?
NCI-H2228 M{j5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJ7LkS1PEDPxE1? NIHOe41USU6JRWK=
MHH-PREB-1 M2fxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPV[HpuUUN3ME2yPU42PTB3IN88US=> MXjTRW5ITVJ?
ChaGo-K-1 M3;BZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrsTWM2OD1{OT62NFk4KM7:TR?= M{\ucnNCVkeHUh?=
KY821 M{jlNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJ7Lk[0N|Mh|ryP M{PqPHNCVkeHUh?=
NCI-H209 MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnTZYdKSzVyPUK5Mlg{PjZizszN MWDTRW5ITVJ?
NBsusSR NFvB[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHkTWM2OD1{OT65PVA1KM7:TR?= MV\TRW5ITVJ?
NCI-H1304 NV3wbZU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4m5cWlEPTB;M{CuOVcyPiEQvF2= MWLTRW5ITVJ?
NB14 M2rXWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDKNIpzUUN3ME2zNU4xPDR4IN88US=> M1jBdXNCVkeHUh?=
HCC1419 NXLXN|dwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37RT2lEPTB;M{GuNlQh|ryP NFHmZZlUSU6JRWK=
KG-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTNzLke0Nlkh|ryP MW\TRW5ITVJ?
A2780 MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnBc|dKSzVyPUOxMlg{PThizszN M3\KN3NCVkeHUh?=
NCI-H28 M1;tV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzuTWM2OD1|MT65PFYyKM7:TR?= M1nXb3NCVkeHUh?=
C2BBe1 NE\XWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[xOJBrUUN3ME2zNk4zPjN2IN88US=> MV;TRW5ITVJ?
VA-ES-BJ NYHEWVRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DFWmlEPTB;M{KuN|Eh|ryP NXfldZp3W0GQR1XS
SBC-5 MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTN{Lki1NVEh|ryP MXTTRW5ITVJ?
OVCAR-4 NWn1bYpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTN|LkS4OFgh|ryP NFzHS2tUSU6JRWK=
COR-L88 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi2S29KSzVyPUO0MlA4PDFizszN NV7YdFdsW0GQR1XS
SW954 NI\TVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTN2LkC3OVIh|ryP MlrsV2FPT0WU
COLO-684 M3m5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr4UYJpUUN3ME2zOE4{PDB2IN88US=> NX\6[nRuW0GQR1XS
HCC70 M1T0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLnTWM2OD1|ND65OVE1KM7:TR?= NY\PeXg4W0GQR1XS
NCI-H1770 MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq0XotMUUN3ME2zOE46PjFizszN NH7qcWlUSU6JRWK=
NCI-H1666 NXnPNVNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jlOWlEPTB;M{WuPFI2OyEQvF2= NEW1S|RUSU6JRWK=
YH-13 MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTN3LkmyJO69VQ>? MlfXV2FPT0WU
DJM-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrm[GhKSzVyPUO2MlgxPDlizszN MXLTRW5ITVJ?
KNS-62 M2CyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX33RnluUUN3ME2zOk46PDN6IN88US=> NVqwTWozW0GQR1XS
SK-MEL-30 NF3WXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LGXGlEPTB;M{euPFc{PyEQvF2= MU\TRW5ITVJ?
SJRH30 NGLreGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorjTWM2OD1|OD63N|QyKM7:TR?= NHyyeIdUSU6JRWK=
GP5d M2WxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjyWnlrUUN3ME2zPE45PjV|IN88US=> NXW4V4ZtW0GQR1XS
SW1116 NIHKT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTN7LkK4NFUh|ryP M3HmZXNCVkeHUh?=
COLO-800 Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPlbHhsUUN3ME2zPU4{PjN6IN88US=> M1jHPXNCVkeHUh?=
RD M2rsb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTN7LkWyOVgh|ryP M4XmbHNCVkeHUh?=
NCI-SNU-5 NULZTo1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTN7Lk[5NVYh|ryP MnjZV2FPT0WU
HuO-3N1 NVzKO3FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTRyLkGwPEDPxE1? MmTHV2FPT0WU
SK-UT-1 NUeyeGZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjJZWZUUUN3ME20NE42Pjd2IN88US=> MlLYV2FPT0WU
SK-MEL-3 NHfUUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDNTWM2OD12MD61PVMzKM7:TR?= MXrTRW5ITVJ?
SK-MEL-28 M3TyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTRyLk[0N|Uh|ryP NFKxW4ZUSU6JRWK=
SCC-4 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Lhd2lEPTB;NEGuNlE{PyEQvF2= MU\TRW5ITVJ?
no-11 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX3TWM2OD12MT63N|U1KM7:TR?= M2jw[3NCVkeHUh?=
HT-144 MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\UZVdCUUN3ME20Nk4xPTZ5IN88US=> MofoV2FPT0WU
MFM-223 NHXFcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1THcWlEPTB;NEKuOFAzKM7:TR?= NVT1XVVEW0GQR1XS
ONS-76 M3[1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLxeo1XUUN3ME20Nk45ODF6IN88US=> NH7GcG1USU6JRWK=
ES8 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjV[FRFUUN3ME20N{4{Pjl6IN88US=> NV7ZNWtqW0GQR1XS
T-24 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzsTWM2OD12Mz60N|Y6KM7:TR?= NVXDVpAxW0GQR1XS
GAMG MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTGZ25vUUN3ME20N{41PTF5IN88US=> NIC0NppUSU6JRWK=
LU-135 NH7XXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Gz[2lEPTB;NESuNFkzOyEQvF2= MnrjV2FPT0WU
HCC1187 MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LyfGlEPTB;NESuPFI3OiEQvF2= MoXmV2FPT0WU
TE-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e5SGlEPTB;NEWuNVY2PCEQvF2= M1\2[nNCVkeHUh?=
J-RT3-T3-5 M4DsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37rRmlEPTB;NEWuOFMyPSEQvF2= NH3QNZpUSU6JRWK=
GI-ME-N NHHzOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7NTWM2OD12NT64PVUzKM7:TR?= NXLwc5M3W0GQR1XS
D-392MG MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTR3LkmyOVYh|ryP MWnTRW5ITVJ?
KALS-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEiwbG1KSzVyPUS2MlczPTdizszN NFXFOmdUSU6JRWK=
MMAC-SF NVHBdHFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLWTWM2OD12Nj65PVUzKM7:TR?= MXXTRW5ITVJ?
HSC-3 NGrZR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HUcWlEPTB;NEeuN|YxQCEQvF2= M1fDNnNCVkeHUh?=
KM-H2 MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXnTWM2OD12Nz62NFA4KM7:TR?= M4Ly[nNCVkeHUh?=
LoVo NULjSpo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;pVnl2UUN3ME20PE4yODB{IN88US=> MV;TRW5ITVJ?
NCI-H510A MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vKTGlEPTB;NEiuNVg4OSEQvF2= MlTNV2FPT0WU
EW-11 NV[0dVJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTR6LkKzOFgh|ryP NEPGXWxUSU6JRWK=
HCC2998 NYeyVJBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPiSoNKSzVyPUS4MlYzOzZizszN Mm\DV2FPT0WU
J82 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTR6LkeyOFIh|ryP NWjZcnNZW0GQR1XS
ML-2 NF3yXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDFXJpKSzVyPUS5MlQ3ODVizszN M{fXcHNCVkeHUh?=
NCI-H2030 M3rUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTR7LkexNVch|ryP M37zN3NCVkeHUh?=
NCI-H1792 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXDOZF2UUN3ME20PU45PTF6IN88US=> NXTXNJdiW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AMPKα / AMPKα / p-AMPKβ1 / AMPKγ2 / p-LKB1 / LKB1 / CaMKIIβ ; 

PubMed: 23677989     


Dose-dependent analysis of AMPK-related molecules in HCC cells. Cells were exposed to nilotinib at the indicated concentrations for 24 h.

DNMT1 / DNMT3a / DNMT3b ; 

PubMed: 28720666     


Kasumi-1 or MV4-11 cells were treated for 24 h with the indicated doses of nilotinib and subjected western blot analysis to detect the expression levels of DNMT1, DNMT3a, DNMT3b.

pABL1 / p-NF-κB1 / NF-κB / STAT3 / p-STAT3 / IL-1β / IL-6 / COX2 ; 

PubMed: 31396300     


ABL1 regulated the inflammation signaling pathway. Blocking activities of ABL1 with Imatinib and Nilotinib inhibits the inflammatory signaling pathway including activities of NF-κB1, STAT3, IL-1β, IL-6, and COX2.

23677989 28720666 31396300
Growth inhibition assay
Cell viability; 

PubMed: 23677989     


Dose-dependent effects of nilotinib on cell viability. HCC cells were treated with nilotinib at the indicated concentrations for 72 h. Cell viability was measured by MTT assay. Points, mean; bars, S.D. (n = 8). 

23677989
In vivo Nilotinib reduces collagen deposition and α-SMA expression in CCl4 and BDL-induced fibrosis. Nilotinib could induce HSC undergoing apoptosis, which is correlated with downregulation of bcl-2. [2] Nilotinib attenuates the extent of lung injury and fibrosis. Nilotinib therapy significantly reduces the levels of hydroxyproline on days 14 and 21, which is accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFRβ. [5] AMN107 prolongs survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolongs survival in imatinib-resistant CML mouse models. [6]

Protocol

Cell Research:[4]
- Collapse
  • Cell lines: Human primary Schwann and schwannoma cells
  • Concentrations: 1-10 μM
  • Incubation Time: 72 hours
  • Method: Human primary Schwann and schwannoma cells are seeded on precoated 96-well plates. Nilotinib is added 40 minutes before stimulation with 100 ng/mL PDGF-DD, and cells are cultured for 72 hours (3 days). Because the half-life of Nilotinib is 18 hours, one-half of the originally added concentrations are added freshly every day. In addition to DAPI staining and determination of the total cell number, the more sensitive and accurate BrdU incorporation method is used to detect proliferating cells. Total cell amount (DAPI) and number of dividing cells (BrdU-positive) are blindly counted using an inverted fluorescent microscope and 200 × magnification. All cells in every well are counted. The total cell number per well differed between various cell batches and is 100–300 cells/well.
    (Only for Reference)
Animal Research:[6]
- Collapse
  • Animal Models: Systemic 32D Bcr-Abl leukemia model in Female BALB/c mice, Bioluminescent Bcr-Abl model of CML in Female NOD-SCID mice and Bone marrow transplant Bcr-Abl model of CML in syngeneic Balb/c recipient mice
  • Formulation: 10% NMP-90% PEG300, PEG300
  • Dosages: 75 mg/kg, 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (50.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 529.52
Formula

C28H22F3N7O

CAS No. 641571-10-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04002674 Recruiting Drug: Placebo oral capsule|Drug: Nilotinib Oral Capsule Dementia With Lewy Bodies Georgetown University|National Institutes of Health (NIH) November 2019 Phase 2
NCT03942094 Not yet recruiting Drug: Nilotinib Chronic Myeloid Leukemia Chronic Phase|Nilotinib Shenzhen Second People''s Hospital June 1 2019 Phase 3
NCT03874858 Recruiting Drug: Nilotinib Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis March 22 2019 Phase 2
NCT02973711 Suspended Drug: Nilotinib|Drug: Ruxolitinib Leukemia Chronic Myeloid University of Michigan Rogel Cancer Center January 18 2018 Phase 1|Phase 2
NCT03228303 Not yet recruiting Drug: Nilotinib 150 MG [Tasigna]|Drug: Imatinib 400mg Chronic Myeloid Leukemia Assiut University December 1 2017 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use AMN-107 for in vivo studies in mice, can you give me some suggestions about the in vivo formulation?

  • Answer:

    For in vivo study, we recommend to use 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 3mg/ml.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Related Bcr-Abl Products

Tags: buy Nilotinib (AMN-107) | Nilotinib (AMN-107) supplier | purchase Nilotinib (AMN-107) | Nilotinib (AMN-107) cost | Nilotinib (AMN-107) manufacturer | order Nilotinib (AMN-107) | Nilotinib (AMN-107) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID